News 2005

Pharmidex CEO voted entrepreneur of the year

London, July 2005.Alan Palmer, co-founder of Pharmidex, has been awarded the prestigious London Biotechnology Entrepreneur of the Year Award 2005 at a meeting in the British Library. With 250 delegates, the meeting brought together companies from Oxford, Cambridge and London.
"Receiving the London Biotechnology Entrepreneur of the Year Award 2005 is not only an honour for me, but also a great honour form my colleague and co-founder, Dr Mohammad Alavijeh along with the whole Pharmidex team.," said Dr Palmer. “As the company moves forward, we will continue to realize our business potential by actively listening to customers and effectively responding to their needs. This, coupled with our unique offering, has allowed us to establish an extensive international client base, which we now aim to consolidate and expand through delivering a value-adding services underpinned by continuous innovation."
“Dr Palmer, along with and his co-founder Dr Alavijeh, clearly illustrate that entrepreneurship requires the determined and persistent pursuit of a vision that is not only commercially viable, but also facilitates the delivery of new medicines to market.” said Tony Jones, London First Director of Biotechnology & Healthcare and a judge of the London Biotechnology 2005 Entrepreneur of the Year award. “Their ability to compete effectively on the International stage was recognised earlier in the year when they won the UK Trade and Investment award as ‘Service Company of the Year’ – they are the first biotech company to win this award. Pharmidex has great growth potential and look set to become a major force within the drug discovery sector. This is precisely what we need to drive biotech in London and in the UK as a whole.”


Pharmidex win Service Company of the Year Award

London, June 2005. Pharmidex have just won the Award of Service Company of the Year at a ceremony held at Madame Tussauds in London. ‘This is the first biotech company to win this award’ said Chris Parsons from UK Trade and Investment. The judges were very impressed by the quality and intensity of their international sales effort along with rock-solid endorsements from major industry figures worldwide’.

‘We are delighted to be recognised for our success in establishing an international client base’ said Dr Alan Palmer, Pharmidex’s. Chief Executive. ‘With an offering that is both innovative and unique, we are working with drug discovery companies worldwide to improve the efficiency, speed and effectiveness by which new medicines are discovered and developed, particularly for disorders of the central nervous system’ Dr Palmer received the award with the co-founder and Chief Operating Officer of Pharmidex, Dr Mohammad Alavijeh. Dr Alavijeh said: ‘the Passport to Export scheme has been instrumental in establishing and implementing our overseas sales strategy – we very much look forward to further growth in the years ahead’
 

News 2004

Pharmidex facilitates workshop on the role of DMPK in R&D for neurodegenerative disorders
July 2004, London

The Pharmidex enquiry into CNS drug discovery
March 2004, Coral Gables, Florida